A randomised, double-blind trial comparing mibefradil and amlodipine: Two long acting calcium antagonists with similar efficacy but different tolerability profiles

Journal of Human Hypertension

Volumn 11, Issue 6, 1997, Pages 387-393

  Viskoper, R J ^a   Bernink, P J L M ^b   Schelling, A ^c   Ribeiro, A B ^d   Kantola, I M ^e   Wilkins, M R ^f   Kobrin, I ^g  

^a BARZILAI MEDICAL CENTER   (Israel)

^b MARTINI HOSPITAL   (Netherlands)

^c SINT FRANCISCUS GASTHUIS   (Netherlands)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g HOFFMANN LA ROCHE INC   (United States)

Author keywords

Amlodipine; Antihypertensives; Calcium antagonists; Mibefradil

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; MIBEFRADIL;

ADULT; AGED; ANGINA PECTORIS; ANKLE EDEMA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ESSENTIAL HYPERTENSION; FEMALE; FLUSHING; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; VERTIGO;

EID: 0030846413     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000453     Document Type: Article

References (23)

1. Oparil S, Calhoun DA. The calcium antagonists in the 1990s: an overview. Am J Hypertens 1991; 4: 396S-405S.
2. Mehta JL et al. Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. Am Heart J 1993; 125: 1704-1710.
3. Mroczek WJ, Barris JF, Allenby KS. A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. J Cardiovasc Pharmacol 1988; 12 (Suppl 7): S79-S84.
4. Osterloh IH. An update on the safety of amlodipine. J Cardiovasc Pharmacol 1991; 17 (Suppl 1): S65-S68.
5. 2+ channel in cardiac tissue. Eur J Pharmacol 1995; 290: 155-158.
6. 2+ channels by Ro 40-5967. Circ Res 1994; 75: 144-148.
7. Clozel J-P et al. Ro 40-5967: a new non-dihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991; 9: 4-17.
8. Welker HA et al. Ro 40-5967: pharmacokinetics of a new calcium antagonist. Eur J Clin Pharmacol 1989; 36 (Suppl): A304.
9. Bernink PJLM et al. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967). Hypertension 1996; 27: 426-432.
10. Bakx ALM et al. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Am Heart J 1995; 130: 748-757.
11. Schmitt R et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992; 52: 314-323.
12. Rousseau MF et al. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol 1996; 28(4): 972-979.
13. Ezzaher A et al. Increased negative inotropic effect of calcium-channel blockers in hypertrophied and failing rabbit heart. J Pharmacol Exp Ther 1991; 257: 466-471.
14. 3H] desmethoxyverapamil receptor, is devoid of negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990; 4: 731-736.
15. Portegies MCM et al. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991; 18: 746-751.
16. Westlake WJ. Symmetrical confidence intervals for bioequivalence. Biometrics 1976; 32: 741-744.
17. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J 1991; 121: 172-177.
18. Thaulow E, Erikssen JE. How important is heart rate? J Hypertens 1991; 9 (Suppl 7): S27-S30.
19. Dyer AR et al. Heart rate as prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980; 112: 736-749.
20. Perski A et al. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 1992; 123: 609-619.
21. Kannel WB et al. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J 1987; 113: 1489-1494.
22. Rofman BA. Long-term open evaluation of amlodipine versus hydrochlorothiazide in patients with essential hypertension. J Cardiovasc Pharmacol 1988; 2 (Suppl 7): 594-597.
23. Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M. Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol. 1996; 77: 713-722.